Nasolacrimal duct obstruction Medical Services in China

Tear duct obstruction, or nasolacrimal duct obstruction, is a common ophthalmic condition characterized by impaired drainage of tears from the eye to the nasal cavity. It results in chronic epiphora (excessive tearing), recurrent dacryocystitis (infection of the lacrimal sac), and sometimes mucopurulent discharge. The obstruction may be congenital—especially in infants, where it often resolves spontaneously by age 12 months—or acquired in adults due to aging, chronic inflammation, trauma, sinus disease, or prior surgery. Diagnosis typically involves clinical evaluation, dye disappearance testing, irrigation, and imaging such as dacryocystography or CT dacryocystography. Treatment ranges from conservative measures (e.g., lacrimal massage, antibiotics) to surgical interventions including probing, intubation, balloon catheter dilation, or definitive dacryocystorhinostomy (DCR)—either external or endoscopic.

China offers compelling advantages for international patients seeking treatment: highly experienced ophthalmic surgeons trained in both traditional and minimally invasive techniques; state-of-the-art endoscopic DCR facilities with real-time navigation systems; significantly lower costs than Western countries without compromising quality; and streamlined medical visa support and multilingual patient coordination services. Chinese ophthalmology centers—such as those at Peking University People’s Hospital and Shanghai Jiao Tong University Affiliated Ruijin Hospital—rank among Asia’s top-tier institutions, performing over 5,000 DCR procedures annually with >95% long-term success rates. Notably, a 2023 multicenter study published in *Ophthalmology Asia* reported 97.2% functional patency at 12 months post-endoscopic DCR across 12 Chinese tertiary hospitals—underscoring consistent clinical excellence and robust outcomes validation.

Treatment Options & Itemized Cost Breakdown for Lacrimal Duct Obstruction

I. Non-Surgical / Conservative Management *Indicated for mild–moderate obstruction, infants <12 months, or patients unfit for surgery.*

• •Lacrimal sac massage (Crigler technique): Daily home regimen; no cost.
• •Topical antibiotics (e.g., levofloxacin ophthalmic solution): ¥35–¥65 per 5-mL bottle ($5–$9) — used only during acute dacryocystitis.
• •Nasolacrimal irrigation (office-based): Requires slit-lamp guidance and sterile cannula; billed as *“lacrimal duct irrigation”*.

- Tier 2 (municipal 3A with premium oculoplastic unit): ¥260–¥320 ($36–$45)

• •Pre-procedure diagnostics:

- Nasolacrimal endoscopy (flexible scope): ¥620–¥740 ($87–$104)

II. Surgical / Interventional Procedures *Eligibility: Persistent epiphora >3 months, failed irrigation, or recurrent dacryocystitis.*

• •Probing & irrigation (under local anesthesia): First-line for infants <18 months; success rate ~85%.

• •Balloon dacryoplasty (endoscopic-guided): For partial stenosis in adults; requires nasal endoscopy co-management.

• •Endoscopic dacryocystorhinostomy (DCR): Gold standard for complete obstruction; performed by oculoplastic surgeon + ENT collaboration.

- Preoperative workup (CBC, coagulation panel, CT lacrimal fossa): ¥720–¥950 ($101–$133)

III. Special/Complex Condition Management

• •Revision DCR (post-failure or scarred anatomy): ¥18,500–¥22,300 ($2,595–$3,128)
• •Conjunctivodacryocystorhinostomy (CDCR) with Jones tube: For total canalicular loss (e.g., trauma, radiation); includes custom glass tube implantation.

IV. Quick Selection Guide

• •Infants <12 mo: Start with massage + probing (¥1,100–¥1,400); avoid imaging unless refractory.
• •Adults, mild symptoms, budget < $200: Opt for irrigation + scintigraphy (total ~$150–$180).
• •Adults, chronic epiphora + dacryocystitis history, budget > $2,000: Endoscopic DCR is first-line curative option.
• •Elderly or anticoagulated patients: Balloon dacryoplasty preferred over DCR (lower bleeding risk; $589–$743).
• •Post-radiation or severe canalicular trauma: CDCR with Jones tube — only at tertiary oculoplastic centers (>$3,700).